GLP-1 titration schedule
Every published GLP-1 escalation schedule, laid out side by side — what each FDA label specifies for Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo, each label’s missed-dose rule, what clinics publish, and what each retatrutide trial administered. No schedule on this page is Prof. Peptide’s own; each table reports one document.
Topic: Comparing published GLP-1 escalation schedules
Audience: Anyone comparing a schedule against its source, across products
Reading time: 6–8 minutes
Not affiliated with Novo Nordisk or Eli Lilly. Prof. Peptide is not affiliated with, endorsed by, or sponsored by either company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S; Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. This page reports what each company’s own prescribing information and trial disclosures state; it sets no schedule of its own.
What this page reports
Five FDA-approved products share a mechanism — GLP-1 or dual GIP/GLP-1 receptor agonism — and each escalates its dose on a schedule its own label specifies: four peptides (Ozempic and Wegovy, semaglutide; Mounjaro and Zepbound, tirzepatide) and Foundayo, a small-molecule GLP-1 drug taken as a daily tablet. Wegovy has a tablet ladder of its own, and “Ozempic” now also names a diabetes tablet on the Rybelsus label, whose ladder is not covered here. The schedules are not identical: they differ in starting dose, step size, and step interval, because each was set against that product’s own trial program and approved indications. This page transcribes each label’s own section 2 (Dosage and Administration) into one table per product, plus what five retatrutide trials administered — retatrutide has no approved product and therefore no label to read, so its section reports trial arms instead.
No table below is compared against another, ranked, or combined into a single recommended path. Reading the labels side by side is useful for seeing how they differ; it is not the same as one of them applying to a different product, and this page does not suggest otherwise. Each product’s own dosing guide covers its trials, warnings, and adverse-event tables in full; this page is the schedules alone, for comparison.
Ozempic (semaglutide)
Section 2 of Ozempic’s prescribing information — DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, effective 2026-06-01.
| Step | Dosage | As specified by the label |
|---|---|---|
| Initiation | 250 mcg once weekly | For 4 weeks. The label states this dosage is to reduce the risk of gastrointestinal adverse reactions during initiation, not for glycemic control. |
| First increase | 500 mcg once weekly | After 4 weeks on the 250 mcg dosage. |
| Second increase (if needed) | 1,000 mcg (1 mg) once weekly | After at least 4 weeks on the 500 mcg dosage, if additional glycemic control is needed. |
| Maximum dosage (if needed) | 2,000 mcg (2 mg) once weekly | After at least 4 weeks on the 1,000 mcg (1 mg) dosage, if additional glycemic control is needed. |
| Chronic kidney disease maintenance | 1,000 mcg (1 mg) once weekly | After at least 4 weeks on the 500 mcg dosage — the label states this dosage specifically to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in patients with type 2 diabetes and chronic kidney disease. |
Full Ozempic dosing guide — trials, boxed warning, and adverse-event tables from the same label. See also the semaglutide profile.
Wegovy (semaglutide)
Section 2 of Wegovy’s prescribing information — DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, effective 2026-06-18.
| Step | Dosage | As specified by the label |
|---|---|---|
| Initiation | 250 mcg once weekly | Weeks 1–4, for all approved indications. |
| First increase | 500 mcg once weekly | Weeks 5–8. |
| Second increase | 1,000 mcg (1 mg) once weekly | Weeks 9–12. |
| Third increase | 1,700 mcg (1.7 mg) once weekly | Weeks 13–16. |
| Maintenance — cardiovascular risk reduction | 2,400 mcg (2.4 mg) (recommended) or 1,700 mcg (1.7 mg) once weekly | Week 17 onward; the label states to consider treatment response and tolerability when selecting between the two. |
| Maintenance — weight reduction | 1,700 mcg (1.7 mg) or 2,400 mcg (2.4 mg) (recommended) once weekly | Week 17 onward; if 2,400 mcg (2.4 mg) is tolerated for ≥4 weeks and additional weight reduction is clinically indicated, the label permits escalation to a maximum of 7,200 mcg (7.2 mg) once weekly. |
Full Wegovy dosing guide — trials, boxed warning, and adverse-event tables from the same label. See also the semaglutide profile.
Wegovy tablets (semaglutide)
Section 2 of Wegovy tablets’s prescribing information — DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, effective 2026-06-18.
| Step | Dosage | As specified by the label |
|---|---|---|
| Starting dosage | 1,500 mcg (1.5 mg) once daily | Days 1–30. |
| First increase | 4,000 mcg (4 mg) once daily | Days 31–60. |
| Second increase | 9,000 mcg (9 mg) once daily | Days 61–90. |
| Maintenance | 25,000 mcg (25 mg) once daily | Day 91 onward, for cardiovascular risk reduction or weight reduction in adults; taken on an empty stomach with up to 4 ounces of water, 30 minutes before food, drink or other oral medicines. |
Full Wegovy tablets dosing guide — trials, boxed warning, and adverse-event tables from the same label. See also the semaglutide profile.
Mounjaro (tirzepatide)
Section 2 of Mounjaro’s prescribing information — DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0, effective 2026-08-27.
| Step | Dosage | As specified by the label |
|---|---|---|
| Starting dosage | 2,500 mcg (2.5 mg) once weekly | The label states this dosage is for treatment initiation, not for glycemic control. |
| Dosage increase | +2,500 mcg (2.5 mg) increments | After at least 4 weeks on the current dose, if additional glycemic control is needed. |
| Maximum dosage — adults | 15,000 mcg (15 mg) once weekly | Reached only through the 2,500 mcg (2.5 mg) step-wise increases above. |
| Maximum dosage — pediatric (10 years and older) | 10,000 mcg (10 mg) once weekly | Reached only through the 2,500 mcg (2.5 mg) step-wise increases above. |
Full Mounjaro dosing guide — trials, boxed warning, and adverse-event tables from the same label. See also the tirzepatide profile.
Zepbound (tirzepatide)
Section 2 of Zepbound’s prescribing information — DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective 2026-08-28.
| Step | Dosage | As specified by the label |
|---|---|---|
| Initiation | 2,500 mcg (2.5 mg) once weekly | For 4 weeks. The label states this dosage is for treatment initiation and is not approved as a maintenance dosage. |
| First increase | 5,000 mcg (5 mg) once weekly | After 4 weeks on the 2,500 mcg (2.5 mg) dosage. |
| Further increases (if needed) | +2,500 mcg (2.5 mg) increments | After at least 4 weeks on the current dose, until the maintenance dosage is reached. |
| Maintenance — weight reduction | 5,000 mcg (5 mg), 10,000 mcg (10 mg), or 15,000 mcg (15 mg) once weekly | The label states to consider treatment response and tolerability when selecting the maintenance dosage. |
| Maintenance — obstructive sleep apnea | 10,000 mcg (10 mg) or 15,000 mcg (15 mg) once weekly | The label states to consider treatment response and tolerability when selecting the maintenance dosage. |
| Maximum dosage | 15,000 mcg (15 mg) once weekly | For all approved indications. |
Full Zepbound dosing guide — trials, boxed warning, and adverse-event tables from the same label. See also the tirzepatide profile.
Foundayo (orforglipron)
Section 2 of Foundayo’s prescribing information — DailyMed setid 8ac446c5-feba-474f-a103-23facb9b5c62, effective 2026-07-29.
| Step | Dosage | As specified by the label |
|---|---|---|
| Starting dosage | 800 mcg once daily | Orally, with or without food. |
| First increase | 2,500 mcg (2.5 mg) once daily | After at least 30 days on 800 mcg. |
| Second increase | 5,500 mcg (5.5 mg) once daily | After at least 30 days on 2,500 mcg (2.5 mg). |
| Further increases (if needed) | 9,000, 14,500 or 17,200 mcg (9, 14.5 or 17.2 mg) once daily | Each after at least 30 days on the current dosage. |
| Maximum dosage | 17,200 mcg (17.2 mg) once daily | 9,000 mcg (9 mg) once daily with a strong CYP3A4 inhibitor. |
Full Foundayo dosing guide — trials, boxed warning, and adverse-event tables from the same label.
Missed doses, by label
The labels set different missed-dose windows, so one product’s rule does not carry over to another: 5 days for Ozempic, 4 days for Mounjaro and Zepbound, and a 2-day rule for Wegovy injection.
| Product | Missed-dose rule, as the label states it |
|---|---|
| Ozempic | A missed dose is administered within 5 days; if more than 5 days have passed, it is skipped. |
| Wegovy injection | If the next dose is more than 2 days away, the missed dose is administered as soon as possible; if less than 2 days away, it is skipped. After 2 or more missed doses in a row, escalation restarts at a lower dosage. |
| Wegovy tablets | The missed dose is skipped and the next dose is taken the following day. |
| Mounjaro and Zepbound | A missed dose is administered within 4 days (96 hours); if more than 4 days have passed, it is skipped. The weekly day can change if doses stay at least 3 days (72 hours) apart. |
| Foundayo | A missed dose is taken as soon as possible, without doubling the next dose; after 7 or more missed doses in a row, escalation restarts at a lower dosage. |
How do clinics titrate GLP-1 drugs?
Clinics that publish a titration schedule for the approved drugs reproduce the labels: semaglutide at 250 mcg in weeks 1–4, then 500 mcg, 1,000 mcg (1 mg) and 1,700 mcg (1.7 mg), to 2,400 mcg (2.4 mg) from week 17; tirzepatide at 2,500 mcg (2.5 mg), stepped up by 2,500 mcg (2.5 mg) every four weeks to a ceiling of 15,000 mcg (15 mg). One clinic adds that the schedule that matters is the one the prescriber writes, and that not every patient reaches the top dose. A clinic selling Foundayo prints its label ladder, 30 days a step. Clinic schedules for compounded semaglutide and tirzepatide sit at or below the label ladders, and are on the semaglutide and tirzepatide dosing guides.
FDA reports adverse events in patients prescribed compounded semaglutide or tirzepatide “in doses beyond what is in the FDA-approved drug label,” including increasing the amount more quickly than the label’s titration schedule; some were serious. FDA states that retatrutide cannot be used in compounding under federal law.
Retatrutide trial dose ladders
Retatrutide is investigational, with no FDA-approved product and therefore no label to read. The five trials below are the ones the retatrutide dosing guide covers in full, with each trial’s doses studied. The escalation column reports only what each trial’s own registry entry, paper or release states.
| Trial | Doses studied | Escalation, as stated | Citation |
|---|---|---|---|
| Phase 2 — Obesity | 1,000 mcg (1 mg), 4,000 mcg (4 mg), 8,000 mcg (8 mg), 12,000 mcg (12 mg) once weekly | Arms started at 2,000 mcg (2 mg) or 4,000 mcg (4 mg), the 12,000 mcg (12 mg) arm at 2,000 mcg (2 mg); the trial's liver-fat substudy paper states that, where applicable, dose escalations occurred every 4 weeks (Nat Med 2024, PMID 38858523). | NCT04881760 Jastreboff AM, Kaplan LM, Frías JP, et al. N Engl J Med. 2023;389:514–526. |
| Phase 2 — Type 2 Diabetes | 500 mcg, 4,000 mcg (4 mg), 8,000 mcg (8 mg), 12,000 mcg (12 mg) once weekly (plus a dulaglutide 1,500 mcg (1.5 mg) active-comparator arm) | The 4,000 mcg (4 mg) and 8,000 mcg (8 mg) arms each split between two starting-dose strategies (4,000 mcg (4 mg): start at 2,000 mcg (2 mg), or no escalation; 8,000 mcg (8 mg): start at 2,000 mcg (2 mg) or at 4,000 mcg, 4 mg), per the registry arms; the step interval is not stated in the abstract. | NCT04867785 Rosenstock J, Frías J, Jastreboff AM, et al. Lancet. 2023;402:529–544. |
| TRIUMPH-1 — Phase 3, Obesity | 4,000 mcg (4 mg), 9,000 mcg (9 mg), 12,000 mcg (12 mg) once weekly | Not public: the registry lists the arms as "Retatrutide Dose 1", "Dose 2" and "Dose 3" with no milligram values or step lengths (last update posted August 21, 2026), and the paper's abstract states no escalation. | NCT05929066 Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med 2026 (PMID 42814954). |
| TRIUMPH-4 — Phase 3, Obesity + Knee Osteoarthritis | 9,000 mcg (9 mg), 12,000 mcg (12 mg) once weekly | No published escalation schedule; the results are Lilly's topline announcement, not a peer-reviewed paper. | NCT05931367 Eli Lilly and Company, topline results announcement, December 2025; not yet peer-reviewed. |
| TRANSCEND-T2D-1 — Phase 3, Type 2 Diabetes | 4,000 mcg (4 mg), 9,000 mcg (9 mg), 12,000 mcg (12 mg) once weekly | Not stated in the Lancet abstract. | NCT06354660 Bajaj HS et al. TRANSCEND-T2D-1: a double-blind, randomized, phase 3 trial. Lancet 2026;407:2402-2413 (PMID 42250575). |
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Related pages
- How to Verify a Peptide COA at the Testing LaboratoryWhich laboratories publish a searchable certificate index, which issue per-record access codes, and how a vendor's certificate can be checked against the laboratory's…
- How Is BPC-157 Dosed? Study Doses, Clinic Protocols and Side EffectsHow BPC-157 has been dosed: the three published human pilots, the 2005 enema study FDA cites, three registered trials, and the range clinics publish, each figure…
- Guides — Practical Peptide Research ReferencesPractical reference guides for peptide research — injection technique, reconstitution math, syringe sizing, and research fundamentals.
Checked and updated
